Effect of appointment of a complex of amino acids on the level of human-beta-defensin-1 and liver function on the background of antituberculosis therapy

Objective — to investigate influence of amino acids appointment on Human-beta-defensin-1 level and liver function in patients with pulmonary tuberculosis who take anti-tuberculosis treatment.Materials and methods. 100 patients with pulmonary tuberculosis were included in the study. 8 of them were subsequently excluded from the study due to treatment interruption, while another 92 patients were divided into 3 groups: 46 patients of Group 1 did not receive additional therapy, 23 patients of Group 2 received essential amino acids in tablet form for 30 days and patients of Group 3 received injectable essential amino acids for 10 days and then amino acids in tablet form for 20 days. Effectiveness of intensive phase was determined basing on cessation of bacterial excretion and appearance of positive X-ray dynamics in form of consolidation of infiltrates and healing of cavities or their size’s decreasing.Results and discussion. Comparison of Human-beta-defensin-1 in groups after 2 months of treatments how edit shighest level inGroup 1 ((45.19 ± 8.67) µmol/L, median — 51.10 µmol/L), the lower one in Group 2 ((9.43 ± 2.97) µmol/L, median — 3.46 µmol/L) and the lowest level in Group 3 ((7.30 ± 1.21) µmol/L, median — 6.04 µmol/L), p < 0.05. Comparison of ALT in groups after 2 months of treatment showed its highest level in Group 1 (1.2 ± 0.2 µmol/L, median — 1.1 µmol/L) and significantly lower level in Group 2 ((0.4 ± 0.1) µmol/L, median — 0.4 µmol/L) and Group 3 ((0.5 ± 0,1) µmol/L, median — 0.4 µmol/L), p < 0.05. Comparison of AST in groups after 2 months of treatment showed its highest level in Group 1 ((0.93 ± 0.13) µmol/L, median — 0,71 µmol/L) and significantly lower level in Group 2 ((0.34 ± 0.04) µmol/L, median — 0.35 µmol/L) and Group 3 ((0.29 ± 0.04) µmol/L, median — 0.30 µmol/L), p < 0.05. Comparison of thymol test in groups showed the lowest result in Group 1 ((4.08 ± 0.44) U, median — 3.25 U), the higher one n Group 2 ((4.38 ± 0.58) U, median — 4.40 U) and the highest result in Group 3 ((5.99 ± 0.79) U, median — 6.30 U), p < 0.05.Conclusions. The inclusion of a complex of amino acids in the pathogenetic therapy of pulmonary tuberculosis increases the effectiveness of the intensive phase of anti-tuberculosis therapy, reduces the hepatotoxic effect of anti-tuberculosis drugs and stimulates the production of Human-beta-defensin-1, which leads to an earlier and balanced immune response. The appointment of a complex of amino acids according to a scheme including the use of an injectable form of the drug has a more pronounced positive effect than the isolated use of a tablet form.